These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Current understanding of Alzheimer's disease diagnosis and treatment. Weller J; Budson A F1000Res; 2018; 7():. PubMed ID: 30135715 [TBL] [Abstract][Full Text] [Related]
5. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Ossenkoppele R; van der Kant R; Hansson O Lancet Neurol; 2022 Aug; 21(8):726-734. PubMed ID: 35643092 [TBL] [Abstract][Full Text] [Related]
6. New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease. Park SA; Han SM; Kim CE Exp Mol Med; 2020 Apr; 52(4):556-568. PubMed ID: 32284537 [TBL] [Abstract][Full Text] [Related]
7. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity. Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453 [TBL] [Abstract][Full Text] [Related]
8. Marking the markers of Alzheimer's: too good to diagnose, too bad to use? Olah Z; Pakaski M; Janka Z; Kalman J Neuropsychopharmacol Hung; 2012 Sep; 14(3):165-76. PubMed ID: 22987730 [TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Holtzman DM Neurobiol Aging; 2011 Dec; 32 Suppl 1(Suppl 1):S4-9. PubMed ID: 22078172 [TBL] [Abstract][Full Text] [Related]
10. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid τ protein in differential diagnosis of Alzheimer's disease and vascular dementia in Chinese population: a meta-analysis. Liu B; Tang Y; Shen Y; Cen L; Han M Am J Alzheimers Dis Other Demen; 2014 Mar; 29(2):116-22. PubMed ID: 24164930 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease. Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384 [TBL] [Abstract][Full Text] [Related]
13. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Thijssen EH; La Joie R; Strom A; Fonseca C; Iaccarino L; Wolf A; Spina S; Allen IE; Cobigo Y; Heuer H; VandeVrede L; Proctor NK; Lago AL; Baker S; Sivasankaran R; Kieloch A; Kinhikar A; Yu L; Valentin MA; Jeromin A; Zetterberg H; Hansson O; Mattsson-Carlgren N; Graham D; Blennow K; Kramer JH; Grinberg LT; Seeley WW; Rosen H; Boeve BF; Miller BL; Teunissen CE; Rabinovici GD; Rojas JC; Dage JL; Boxer AL; Lancet Neurol; 2021 Sep; 20(9):739-752. PubMed ID: 34418401 [TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Toledo JB; Zetterberg H; van Harten AC; Glodzik L; Martinez-Lage P; Bocchio-Chiavetto L; Rami L; Hansson O; Sperling R; Engelborghs S; Osorio RS; Vanderstichele H; Vandijck M; Hampel H; Teipl S; Moghekar A; Albert M; Hu WT; Monge Argilés JA; Gorostidi A; Teunissen CE; De Deyn PP; Hyman BT; Molinuevo JL; Frisoni GB; Linazasoro G; de Leon MJ; van der Flier WM; Scheltens P; Blennow K; Shaw LM; Trojanowski JQ; Brain; 2015 Sep; 138(Pt 9):2701-15. PubMed ID: 26220940 [TBL] [Abstract][Full Text] [Related]